8-K: CONMED Corporation Announces Strong Fourth Quarter and Full-Year 2024 Financial Results, Projects Continued Growth in 2025

CONMED Corporation reports a solid finish to 2024 with increased sales and earnings, and anticipates further growth in 2025 despite currency headwinds.

Summary

• CONMED Corporation announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Fourth-quarter sales reached $345.9 million, a 5.8% increase year-over-year as reported, and 6.0% in constant currency.
• Domestic revenue for Q4 increased by 6.8% year-over-year, while international revenue rose by 4.4% as reported and 5.0% in constant currency.
• Diluted net earnings per share (GAAP) for Q4 were $1.08, compared to $1.05 in the same period of 2023.
• Adjusted diluted net earnings per share for Q4 were $1.34, a 26.4% increase compared to the fourth quarter of 2023.
• Full-year sales totaled $1,307.0 million, a 5.0% increase year-over-year as reported, and 5.3% in constant currency.
• Domestic revenue for the full year increased by 6.9%, while international revenue rose by 2.6% as reported and 3.4% in constant currency.
• Diluted net earnings per share (GAAP) for the full year were $4.25, compared to $2.04 in 2023.
• Adjusted diluted net earnings per share for the full year were $4.17, a 20.9% increase compared to 2023.
• The company expects full-year 2025 reported revenue between $1.344 billion and $1.372 billion, representing constant currency growth of approximately 4% to 6% with a currency headwind of approximately 100 to 120 basis points.
• Full-year 2025 adjusted diluted net earnings per share are projected to be in the range of $4.25 to $4.40, including a currency headwind of approximately $0.15 to $0.20.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the solid financial results, growth projections, and management's focus on operational improvements. However, the presence of supply chain challenges and currency headwinds tempers the overall optimism.

Positives

• CONMED achieved solid sales and earnings growth in 2024.
• The company saw improved profitability in the fourth quarter of 2024.
• Domestic revenue showed strong growth for both the quarter and the full year.
• CONMED is focused on improving operations and strengthening its foundation for future growth.
• The company's adjusted diluted net earnings per share increased significantly in both Q4 and the full year.

Negatives

• The company faced persistent supply challenges for parts of its business in 2024.
• Currency headwinds are expected to impact revenue growth in 2025 by approximately 100 to 120 basis points.
• Currency headwinds are expected to reduce adjusted diluted net earnings per share by approximately $0.15 to $0.20 in 2025.
• Capital Products sales decreased -12.7% for the quarter and -5.5% for the year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• General industry and economic conditions could impact future performance.
• The company's Annual Report on Form 10-K lists risk factors that could affect results.
• The 2025 outlook excludes any potential impact from recently announced tariffs.

Future Outlook

CONMED expects full-year 2025 reported revenue between $1.344 billion and $1.372 billion, representing constant currency growth of approximately 4% to 6%. The company anticipates full-year 2025 adjusted diluted net earnings per share in the range of $4.25 to $4.40.

Management Comments

• Patrick J. Beyer, CONMED's President and Chief Executive Officer, stated that 2024 was a year of solid sales and earnings growth but also challenging due to persistent supply challenges.
• Mr. Beyer also commented that in 2025, the company is laser-focused on improving operations and strengthening its foundation for future above-market revenue and profitability growth.

Industry Context

CONMED's results reflect the broader trends in the medical technology industry, where companies are navigating supply chain disruptions while striving for growth. The focus on surgical procedures positions CONMED to benefit from the aging population and increasing demand for minimally invasive surgeries.

Comparison to Industry Standards

• Comparing CONMED to similar medical device companies like Stryker, Johnson & Johnson (Medical Devices segment), and Medtronic, CONMED's revenue growth of 5.0% for the full year 2024 is within a reasonable range.
• Stryker reported organic sales growth of 11.5% in 2024, while Medtronic reported 3.8% growth in fiscal year 2024.
• CONMED's focus on improving profitability aligns with industry-wide efforts to optimize operational efficiency and manage costs.
• The projected 4-6% revenue growth for 2025 is a reasonable expectation given the current economic climate and industry trends.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, although currency headwinds may impact returns.
• Employees may benefit from the company's focus on operational improvements and future growth.
• Customers can expect continued access to CONMED's surgical devices and equipment.
• Suppliers may face ongoing supply chain challenges, but CONMED's growth could lead to increased demand.
• Creditors can be reassured by the company's solid financial performance and positive outlook.

Next Steps

• The company's management will host a conference call to discuss the fourth quarter and full-year 2024 results.
• Investors can access the webcast replay of the call on CONMED's website.

Key Dates